CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 100 enrolled
Drug / intervention
Optison echocardiography contrast agentdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01721447
NCT01721447Phase 4Completed
CompareCT.gov

The Use of Optison Echocardiography Contrast in the Detection of Left Atrial Appendage Thrombus With Transesophageal Echocardiography.

University of Utah·interventional·Posted Nov 5, 2012·Updated Aug 20, 2019

In Brief

A Phase 4 clinical trial evaluating Optison echocardiography contrast agent for Atrial Fibrillation. Completed, enrolled 100 participants across 1 site.

Detailed Summary

The investigators intend to determine if using Optison echocardiography contrast increases sensitivity and specificity of detecting left atrial appendage thrombus in transesophageal echocardiography studies as opposed to standard 2D and 3D TEE imaging without the use of echo contrast.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtrial Fibrillation
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedNov 5, 2012
Enrollment StartJun 1, 2013
Primary CompletionMay 1, 2018
TodayJul 2, 2026
Enrollment to primary: 4.9 yearsPosted 13.7 years ago

Interventions

Optison echocardiography contrast agentdrug

Subjects undergoing transesophageal echocardiography who will receive the Optison contrast agent during the procedure to test if the image quality improves to provide accurate assessment of the presence of left atrial thrombus.